<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309708</url>
  </required_header>
  <id_info>
    <org_study_id>HC-G-H-1722</org_study_id>
    <nct_id>NCT04309708</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Assessment for a New UV-protected Pump Infusion Line in Intravenous Infusion Therapy</brief_title>
  <official_title>A Prospective, Randomized, Cntrolled, Multi-center Clinical Study on Efficacy and Safety of Infusion Therapy by Comparing Original Perfusor Line (Orange,Art No.8723017) With Original Perfusor Line (Black,Art No.8723010) in Pump Infusion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Medical International Trading Company Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Medical International Trading Company Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify the efficacy and safety of Original Perfusor Line (Art.No.8723017) in infusion
      therapy in Patients with light sensitive drug infusion.

      Subjects who choose to use Original Perfusor Line for their planned infusion treatment
      (nimodipine injection) as per the study protocol will be enrolled. The 300 subjects will be
      1:1 randomized into the experimental group or the control group, using Original Perfusor Line
      (Art.No. 8723017) connected with an injection pump for infusion treatment with nimodipine
      injection or Original Perfusor Line (Art.No.8723010) connected with an injection pump for
      infusion treatment with nimodipine injection, respectively.Use of both the test product and
      the control product will be in strict accordance with their package insert.

      The primary endpoint is the percentage of products which successful infuse fluids or
      medications into patient's circulatory system without leakage of fluids or medications,
      visible catheter embolism, air embolism and micro embolism in the infusion system and the
      secondary endpoint is the quality assessment for the clinical application of the
      products,such as the percentage of products which are qualified for infusion administration
      including link and removal, transparence, and tenacity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Actual">September 8, 2019</completion_date>
  <primary_completion_date type="Actual">September 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Controlled, Parallel, Multi-center study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Infusion success rate</measure>
    <time_frame>2 hours after infusion therapy completion</time_frame>
    <description>The percentage of products which successful infuse fluids or medications into patient's circulatory system without leakage of fluids or medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Product pass rate</measure>
    <time_frame>2 hours after infusion therapy completion</time_frame>
    <description>percentage of the quantity of products that pass the evaluation in the sum of products that pass the evaluation and products that fail the evaluation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events/Serious Adverse Events during treatment</measure>
    <time_frame>Day -7 (At least 7days before infusion therapy) , Day 0 (infusion therapy), 2 hours after infusion therapy completion</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Blood coagulation Test</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>Including tests of prothrombin time(PT) in second, activated partial thrombophastin time(APTT) in second and thrombin time(TT) in second</description>
  </other_outcome>
  <other_outcome>
    <measure>white blood cell(WBC)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in 10^9/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Neutrophil(NEU)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in 10^9/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Red blood cell(RBC)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in 10^12/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin(HGB)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Hematocrit(HCT)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in percentage(%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelet(PLT)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in 10^9/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood urea nitrogen(BUN)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in mmoL/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum creatinine(SCr)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in umoL/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Urea</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in mmoL/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum alanine transaminase(ALT)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in U/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Aspartate transaminase(AST)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in U/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Alkaline phosphatase(ALP)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in U/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Î³-glutamyl transpeptidase (GGT)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in U/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Total bilirubin(TBIL)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in umoL/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Total protein(TP)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in g/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Albumin(ALB)</measure>
    <time_frame>Day -7(At least 7days before infusion therapy), Day 0 (infusion therapy) , 2 hours after infusion therapy completion</time_frame>
    <description>in g/L</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Original Perfusor Line(Art.No.8723017)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Original Perfusor Line(Art.No.8723010)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nimodipine pump infusion</intervention_name>
    <description>Patients with nimodipine pump infusion with pump infusion line and other infusion equipments</description>
    <arm_group_label>Original Perfusor Line(Art.No.8723010)</arm_group_label>
    <arm_group_label>Original Perfusor Line(Art.No.8723017)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged â¥18 years, all genders;

          -  Patients who will be treated plan to use injection pump for infusion treatment with
             nimodipine injection by infusion pump.

          -  Participated in this study voluntarily and signed informed consent form.

        Exclusion Criteria:

          -  Patients have contraindication on Nimodipine.

          -  Patients allergic to polyethylene (PE) material;

          -  Patients with aspartate transaminase(AST) and alanine transaminase(ALT) are 2 times
             higher than normal range, Serum creatinine(Scr) is 1.5 times higher than normal range.

          -  Patient with malignant tumor, pregnant or Lactation;

          -  Patients had participated in other clinical trials within 1 month and in parallel with
             other trials;

          -  Patients are unsuitable to participate in this study as judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li ping Liu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital, Captial Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xuanwu Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanbo Brain Hospital, Captial Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100093</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pump infusion</keyword>
  <keyword>photodegradation</keyword>
  <keyword>IV infusion therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

